Scholarlink

Background <p>Carbapenem-resistant <i>Enterobacterales</i> (CRE) have become a major global public health concern. The production and spread of carbapenemases have rendered carbapenemase-producing <i>Enterobacterales</i> (CPE) a severe clinical threat. Epidemiological data regarding CPE infections remain scarce in secondary hospitals. This study aims to characterize carbapenemase phenotypes and antimicrobial resistance profiles of CRE isolates from a secondary hospital, and explore factors associated with patient clinical outcome.</p> Methods <p>A cohort study was conducted on clinical CRE isolates collected from January 2023 to September 2024. Carbapenemases were identified by immunochromatography. Univariate and multivariate logistic regression models were conducted to identify factors associated with clinical failure of CPE-infected patients.</p> Results <p>Of 131 strains from enrolled CRE infected patients, the detection rate of carbapenemases was 100% <i>via</i> immunochromatography. Phenotypes distribution revealed 98 (74.8%) <i>Klebsiella pneumoniae</i> carbapenemase (KPC), 25 (19.1%) metallo-β-lactamases (MBL) and 8 (6.1%) double carbapenemases-producer (DCP), with distinct antimicrobial resistance features across groups. Elevated aCCI (aOR 1.4, 95% CI 1.1–1.8, <i>p</i> = 0.007), mechanical ventilation (aOR 7.8, 95% CI 2.2–28.1, <i>p</i> = 0.002) and hospital-onset (aOR 6.7, 95% CI 2.0–23.0, <i>p</i> = 0.002) were independent factors associated with clinical failure.</p> Conclusion <p>The secondary hospitals face intense carbapenemase prevalence pressure and complex resistance profiles, particularly among DCP strains. Patients with more comorbidities and hospital-acquired infection may develop poor clinical outcomes. These findings underscore the urgent need for enzyme-guided precision therapy and tailored infection control strategies in these high-risk, community-linked medical institutions.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Wen Zhu,
  • Yi Liang,
  • Feifei Dai,
  • Chao Weng

摘要

Background

Carbapenem-resistant Enterobacterales (CRE) have become a major global public health concern. The production and spread of carbapenemases have rendered carbapenemase-producing Enterobacterales (CPE) a severe clinical threat. Epidemiological data regarding CPE infections remain scarce in secondary hospitals. This study aims to characterize carbapenemase phenotypes and antimicrobial resistance profiles of CRE isolates from a secondary hospital, and explore factors associated with patient clinical outcome.

Methods

A cohort study was conducted on clinical CRE isolates collected from January 2023 to September 2024. Carbapenemases were identified by immunochromatography. Univariate and multivariate logistic regression models were conducted to identify factors associated with clinical failure of CPE-infected patients.

Results

Of 131 strains from enrolled CRE infected patients, the detection rate of carbapenemases was 100% via immunochromatography. Phenotypes distribution revealed 98 (74.8%) Klebsiella pneumoniae carbapenemase (KPC), 25 (19.1%) metallo-β-lactamases (MBL) and 8 (6.1%) double carbapenemases-producer (DCP), with distinct antimicrobial resistance features across groups. Elevated aCCI (aOR 1.4, 95% CI 1.1–1.8, p = 0.007), mechanical ventilation (aOR 7.8, 95% CI 2.2–28.1, p = 0.002) and hospital-onset (aOR 6.7, 95% CI 2.0–23.0, p = 0.002) were independent factors associated with clinical failure.

Conclusion

The secondary hospitals face intense carbapenemase prevalence pressure and complex resistance profiles, particularly among DCP strains. Patients with more comorbidities and hospital-acquired infection may develop poor clinical outcomes. These findings underscore the urgent need for enzyme-guided precision therapy and tailored infection control strategies in these high-risk, community-linked medical institutions.

Clinical trial number

Not applicable.